Candriam S.C.A. Dr Reddys Laboratories LTD Transaction History

Candriam S.C.A.

$16.3 Billion
Q2 2024

A detailed history of Candriam S.C.A. transactions in Dr Reddys Laboratories LTD stock. As of the latest transaction made, Candriam S.C.A. holds 40,000 shares of RDY stock, worth $3.19 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

40,000

Previous 50,000 20.0%

Holding current value

$3.19 Million

Previous $3.67 Million 16.91%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$68.26 - $76.19 $682,600 - $761,900	-10,000 Reduced 20.0%	40,000 $3.05 Million
Q1 2024 May 03, 2024	BUY	$67.36 - $77.59 $1.35 Million - $1.55 Million	20,000 Added 66.67%	50,000 $3.67 Million
Q4 2023 Feb 14, 2024	BUY	$64.27 - $69.9 $192,810 - $209,700	3,000 Added 11.11%	30,000 $2.09 Million
Q3 2023 Nov 13, 2023	BUY	$61.9 - $72.77 $309,500 - $363,850	5,000 Added 22.73%	27,000 $1.81 Million
Q2 2023 Aug 08, 2023	BUY	$53.34 - $63.11 $213,360 - $252,440	4,000 Added 22.22%	22,000 $1.39 Million
Q1 2023 May 12, 2023	BUY	$51.63 - $56.93 $206,520 - $227,720	4,000 Added 28.57%	18,000 $1.02 Million
Q4 2022 Feb 13, 2023	BUY	$51.15 - $57.45 $716,100 - $804,300	14,000 New	14,000 $724,000
Q3 2020 Oct 19, 2020	SELL	$51.39 - $72.41 $719,460 - $1.01 Million	-14,000 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$39.55 - $54.65 $553,700 - $765,100	14,000 New	14,000 $742,000
Q1 2019 May 02, 2019	SELL	$35.77 - $40.57 $643,860 - $730,260	-18,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$29.25 - $36.73 $526,500 - $661,140	18,000 New	18,000 $623,000

Others Institutions Holding RDY

# of Institutions

233

Shares Held

24M

Call Options Held

14.6K

Put Options Held

2.8K

View Full List

About DR REDDYS LABORATORIES LTD

Ticker RDY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 166,028,992
Market Cap $13.2B
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...

More about RDY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account